Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Proteomics/Modifier Based on Mass Spectrometry Reveals the Pathogenesis of Eclampsia During Pregnancy and the Screening of Disease Markers

NCT04833881 is registered in ClinicalTrials.gov with Heilongjiang University of Chinese Medicine as lead sponsor.

NCT NCT04833881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04833881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Proteomics/Modifier Based on Mass Spectrometry Reveals the Pathogenesis of Eclampsia During Pregnancy and the Screening of Disease Markers
Lead sponsor
Heilongjiang University of Chinese Medicine
Phase
Observational
Overall status
Unknown status
Start date
April 30, 2021
Completion date
November 30, 2024
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

marker screening, mechanism